Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Accumulated Expenses: 2020-2024

Historic Other Accumulated Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $521,639.

  • SAB Biotherapeutics' Other Accumulated Expenses fell 4.56% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 4.56%. This contributed to the annual value of $521,639 for FY2024, which is 8.58% up from last year.
  • SAB Biotherapeutics' Other Accumulated Expenses amounted to $521,639 in FY2024, which was up 8.58% from $480,435 recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Other Accumulated Expenses registered a high of $521,639 during FY2024, and its lowest value of $90,982 during FY2020.
  • In the last 3 years, SAB Biotherapeutics' Other Accumulated Expenses had a median value of $513,110 in 2022 and averaged $505,061.
  • As far as peak fluctuations go, SAB Biotherapeutics' Other Accumulated Expenses skyrocketed by 212.05% in 2021, and later decreased by 6.37% in 2023.
  • SAB Biotherapeutics' Other Accumulated Expenses (Yearly) stood at $90,982 in 2020, then soared by 212.05% to $283,909 in 2021, then surged by 80.73% to $513,110 in 2022, then fell by 6.37% to $480,435 in 2023, then climbed by 8.58% to $521,639 in 2024.